Mastodon

Penicillin G sodium salt (Powder) Instructions for Use

Marketing Authorization Holder

Biochemie GmbH (Austria)

ATC Code

J01CE01 (Benzylpenicillin)

Active Substance

Benzylpenicillin (Rec.INN registered by WHO)

Dosage Form

Bottle Rx Icon Penicillin G sodium salt Powder for solution for injection 1 million IU: fl. 100 pcs.

Dosage Form, Packaging, and Composition

Powder for solution for injection 1 vial
Benzylpenicillin sodium salt 1 million IU

Vials (100) – cardboard boxes.

Clinical-Pharmacological Group

Penicillin antibiotic, destroyed by penicillinase

Pharmacotherapeutic Group

Antibiotic, penicillin

Pharmacological Action

An antibiotic from the group of biosynthetic penicillins. It exerts a bactericidal effect by inhibiting the synthesis of the microorganism’s cell wall.

It is active against gram-positive bacteria: Staphylococcus spp., Streptococcus spp. (including Streptococcus pneumoniae), Corynebacterium diphtheriae, Bacillus anthracis; gram-negative bacteria: Neisseria gonorrhoeae, Neisseria meningitidis; anaerobic spore-forming rods; as well as Actinomyces spp., Spirochaetaceae.

Strains of Staphylococcus spp. that produce penicillinase are resistant to the action of benzylpenicillin. It is destroyed in an acidic environment.

The procaine salt of benzylpenicillin is characterized by a longer duration of action compared to the potassium and sodium salts.

Pharmacokinetics

After intramuscular administration, it is rapidly absorbed from the injection site. It is widely distributed in body tissues and fluids. Benzylpenicillin penetrates well through the placental barrier and the blood-brain barrier when the meninges are inflamed.

T1/2 is 30 minutes. It is excreted in the urine.

Indications

Treatment of diseases caused by microorganisms sensitive to benzylpenicillin: lobar and focal pneumonia, pleural empyema, sepsis, septicemia, pyemia, acute and subacute septic endocarditis, meningitis, acute and chronic osteomyelitis, infections of the urinary and biliary tracts, tonsillitis, purulent infections of the skin, soft tissues and mucous membranes, erysipelas, diphtheria, scarlet fever, anthrax, actinomycosis, treatment of purulent-inflammatory diseases in obstetric and gynecological practice, ENT diseases, eye diseases, gonorrhea, blennorrhea, syphilis.

ICD codes

ICD-10 code Indication
A22 Anthrax
A36 Diphtheria
A38 Scarlet fever
A40 Streptococcal sepsis
A41 Other sepsis
A42 Actinomycosis
A46 Erysipelas
A50 Congenital syphilis
A51 Early syphilis
A52 Late syphilis
A54 Gonococcal infection
A54.3 Gonococcal eye infection
G00 Bacterial meningitis, not elsewhere classified
H10 Conjunctivitis
H15.0 Scleritis
H15.1 Episcleritis
H16 Keratitis
H20 Iridocyclitis
H66 Suppurative and unspecified otitis media
I33 Acute and subacute endocarditis
J01 Acute sinusitis
J02 Acute pharyngitis
J03 Acute tonsillitis
J04 Acute laryngitis and tracheitis
J15 Bacterial pneumonia, not elsewhere classified
J20 Acute bronchitis
J31 Chronic rhinitis, nasopharyngitis and pharyngitis
J32 Chronic sinusitis
J35.0 Chronic tonsillitis
J37 Chronic laryngitis and laryngotracheitis
J42 Unspecified chronic bronchitis
J86 Pyothorax (pleural empyema)
K81.0 Acute cholecystitis
K81.1 Chronic cholecystitis
K83.0 Cholangitis
L01 Impetigo
L02 Cutaneous abscess, furuncle and carbuncle
L03 Cellulitis
L08.0 Pyoderma
L08.8 Other specified local infections of skin and subcutaneous tissue
M86 Osteomyelitis
N10 Acute tubulointerstitial nephritis (acute pyelonephritis)
N11 Chronic tubulointerstitial nephritis (chronic pyelonephritis)
N30 Cystitis
N34 Urethritis and urethral syndrome
N41 Inflammatory diseases of prostate
N70 Salpingitis and oophoritis
N71 Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess)
N72 Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis)
N73.5 Unspecified female pelvic peritonitis
T79.3 Posttraumatic wound infection, not elsewhere classified
ICD-11 code Indication
1A60.Z Congenital syphilis, unspecified
1A61.Z Early syphilis, unspecified
1A62.Z Late syphilis, unspecified
1A72.4 Gonococcal eye infection
1A7Z Gonococcal infection, unspecified
1B50 Scarlet fever
1B70.0Z Erysipelas, unspecified
1B70.1 Streptococcal cellulitis of the skin
1B70.2 Staphylococcal cellulitis of the skin
1B70.Z Bacterial cellulitis or lymphangitis caused by unspecified bacterium
1B72.0 Bullous impetigo
1B72.1 Nonbullous impetigo
1B72.Z Impetigo, unspecified
1B75.0 Furuncle
1B75.1 Carbuncle
1B75.2 Furunculosis
1B75.3 Pyogenic skin abscess
1B7Y Other specified pyogenic bacterial infections of skin or subcutaneous tissue
1B97 Anthrax
1C10.Z Actinomycosis, unspecified
1C17.Z Diphtheria, unspecified
1C44 Non-pyogenic bacterial infections of skin
1D01.0Z Bacterial meningitis, unspecified
1G40 Sepsis without septic shock
9A60.Z Conjunctivitis, unspecified
9A71 Infectious keratitis
9A7Z Diseases of the cornea, unspecified
9A96.0 Anterior uveitis, not associated with systemic diseases
9A96.1 Anterior uveitis, associated with systemic diseases
9A96.Z Anterior uveitis, unspecified
9B50 Episcleritis
9B51 Scleritis
AA9Z Unspecified suppurative otitis media
BB4Z Acute or subacute endocarditis, unspecified
CA01 Acute rhinosinusitis
CA02.Z Acute pharyngitis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA05 Acute laryngitis or tracheitis
CA09 Chronic rhinitis, nasopharyngitis or pharyngitis
CA0A.Z Chronic rhinosinusitis, unspecified
CA0F.Y Other specified chronic diseases of the palatine tonsils and adenoids
CA0G Chronic laryngitis or laryngotracheitis
CA20.1Z Chronic bronchitis, unspecified
CA40.0Z Bacterial pneumonia, unspecified
CA42.Z Acute bronchitis, unspecified
CA44 Pyothorax
DC12.0Z Acute cholecystitis, unspecified
DC12.1 Chronic cholecystitis
DC13 Cholangitis
EA50.3 Staphylococcal scarlet fever
EB21 Pyoderma gangrenosum
FB84.Z Osteomyelitis or osteitis, unspecified
GA01.Z Inflammatory diseases of uterus, except cervix, unspecified
GA05.2 Unspecified pelvic peritonitis in women
GA07.Z Salpingitis and oophoritis, unspecified
GA91.Z Inflammatory and other diseases of prostate, unspecified
GB50 Acute tubulo-interstitial nephritis
GB51 Acute pyelonephritis
GB55.Z Chronic tubulo-interstitial nephritis, unspecified
GB5Z Renal tubulo-interstitial diseases, unspecified
GC00.Z Cystitis, unspecified
GC02.Z Urethritis and urethral syndrome, unspecified
NF0A.3 Posttraumatic wound infection, not elsewhere classified
GA0Z Inflammatory diseases of female genital tract, unspecified
XA5WW1 Cervix uteri

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Individual. It is administered intramuscularly, intravenously, subcutaneously, endolumbally.

For intramuscular and intravenous administration in adults, the daily dose ranges from 250,000 to 60 million IU. The daily dose for children under 1 year of age is 50,000-100,000 IU/kg, over 1 year – 50,000 IU/kg; if necessary, the daily dose can be increased to 200,000-300,000 IU/kg, for vital indications – up to 500,000 IU/kg. The frequency of administration is 4-6 times/day.

For endolumbar administration, depending on the disease and severity of the course, adults are given 5,000-10,000 IU, children – 2,000-5,000 IU. The drug is diluted in sterile water for injection or in 0.9% sodium chloride solution at the rate of 1 thousand IU/ml. Before injection (depending on the level of intracranial pressure), 5-10 ml of cerebrospinal fluid is withdrawn and added to the antibiotic solution in an equal ratio.

Subcutaneously, Benzylpenicillin is used for infiltrate injections (100,000-200,000 IU in 1 ml of 0.25%-0.5% procaine solution).

Benzylpenicillin potassium salt is used only intramuscularly and subcutaneously, in the same doses as benzylpenicillin sodium salt.

Benzylpenicillin procaine salt is used only intramuscularly. The average therapeutic dose for adults: single – 300,000 IU, daily – 600,000 IU. For children under 1 year of age – 50,000-100,000 IU/kg/day, over 1 year – 50,000 IU/kg/day. The frequency of administration is 3-4 times/day.

The duration of treatment with benzylpenicillin, depending on the form and severity of the disease, can range from 7-10 days to 2 months or more.

Adverse Reactions

From the digestive system diarrhea, nausea, vomiting.

Effects due to chemotherapeutic action vaginal candidiasis, oral candidiasis.

From the central nervous system when using benzylpenicillin in high doses, especially with endolumbar administration, neurotoxic reactions may develop: nausea, vomiting, increased reflex excitability, meningism symptoms, convulsions, coma.

Allergic reactions increased body temperature, urticaria, skin rash, rash on mucous membranes, joint pain, eosinophilia, angioedema. Cases of anaphylactic shock with fatal outcome have been described.

Contraindications

Hypersensitivity to benzylpenicillin and other drugs from the group of penicillins and cephalosporins. Endolumbar administration is contraindicated in patients suffering from epilepsy.

Use in Pregnancy and Lactation

Use during pregnancy is possible only if the intended therapeutic benefit for the mother outweighs the potential risk to the fetus.

If use during lactation is necessary, the issue of discontinuing breastfeeding should be decided.

Use in Renal Impairment

Use with caution in patients with impaired renal function.

Pediatric Use

Can be used in children according to indications.

Special Precautions

Use with caution in patients with impaired renal function, heart failure, predisposition to allergic reactions (especially drug allergy), and with hypersensitivity to cephalosporins (due to the possibility of cross-allergy).

If no effect is observed 3-5 days after the start of use, a switch to other antibiotics or combination therapy should be made.

Due to the possibility of fungal superinfection, it is advisable to prescribe antifungal drugs during treatment with benzylpenicillin.

It must be taken into account that the use of benzylpenicillin in subtherapeutic doses or premature discontinuation of treatment often leads to the emergence of resistant strains of pathogens.

Drug Interactions

Probenecid reduces the tubular secretion of benzylpenicillin, resulting in an increase in its plasma concentration and an increase in the half-life.

With simultaneous use with antibiotics that have a bacteriostatic effect (tetracycline), the bactericidal effect of benzylpenicillin is reduced.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS